Faeth Therapeutics shows oral PIKTOR matches or exceeds IV gedatolisib in mouse breast‑cancer models
Faeth Therapeutics presented preclinical data at the ESMO 2026 Congress showing its oral combination PIKTOR halted or reversed tumor growth in HR+/HER2‑ breast‑cancer mouse xenografts, performing as well as or better than the intravenous agent gedatolisib. The triple regimen of PIKTOR with fulvestrant and palbociclib achieved complete growth inhibition or regression. The company said topline results from its Phase 2 endometrial‑cancer trial are expected by year‑end 2026 and interim data from its Phase 1b/2 breast‑cancer trial are slated for 2027.
Why it matters
The data suggest PIKTOR could offer an all‑oral, multi‑node alternative to existing IV therapies, potentially expanding Faeth's market position if clinical trials confirm efficacy. Investors should watch for the upcoming Phase 2 endometrial‑cancer readout (year‑end 2026) and the breast‑cancer interim data (2027).
Key facts
- 1Faeth reported that oral PIKTOR halted tumor growth or caused regression in two HR+/HER2‑ breast‑cancer mouse xenograft models. stocktitan.net
- 2In the same models, PIKTOR performed as well as or better than intravenous gedatolisib. finanznachrichten.de
- 3When combined with fulvestrant and palbociclib, PIKTOR achieved complete tumor growth inhibition or regression. stocktitan.net
- 4A kinase assay showed PIKTOR reduced AKT activity to approximately 10% of uninhibited levels, deeper than other PI3K/mTOR inhibitors. investing.com
- 5Faeth expects topline data from its Phase 2 endometrial‑cancer trial (FTH‑PIK‑201) by year‑end 2026. stocktitan.net
- 6Interim data from its Phase 1b/2 breast‑cancer trial (FTH‑PIK‑101) are anticipated in 2027. stocktitan.net
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.